2012
Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease
Tawara I, Sun Y, Liu C, Toubai T, Nieves E, Evers R, Alrubaie M, Mathewson N, Tamaki H, Reddy P. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal Of Leukocyte Biology 2012, 91: 667-675. PMID: 22262800, PMCID: PMC3317273, DOI: 10.1189/jlb.1011510.Peer-Reviewed Original ResearchConceptsSuppression of GVHDSeverity of GVHDIL-10Donor TregsBM graftsRegulation of GVHDImmune-regulatory cytokinesInterleukin-10 contributeAcute GVHDClinical GVHDGVHD severityHost diseaseDonor graftsGVHDPreclinical modelsTregsGene polymorphismsExperimental graftCellular subsetsGraftSeverityHost cellsFunctional relevanceHost tissuesIL
2010
Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro
Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro. International Journal Of Radiation Biology 2010, 87: 71-80. PMID: 20958220, PMCID: PMC3806980, DOI: 10.3109/09553002.2010.518208.Peer-Reviewed Original ResearchMeSH KeywordsAgedApoptosisBcl-2-Associated X ProteinCarcinoma, HepatocellularCaspase 3Cell ProliferationDose-Response Relationship, RadiationFas ReceptorFemaleGamma RaysHumansIn Vitro TechniquesInterferon-gammaInterleukin-10Liver NeoplasmsMaleMiddle AgedRadiation ToleranceT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsEffector T cellsAdvanced hepatocellular carcinomaRegulatory T cellsT cellsHepatocellular carcinomaLow-dose gamma raysLow-dose irradiationApoptosis-related proteinsImmune responseLow dosesEnhanced immune responseCaspase-3Dose-dependent reductionB-cell lymphoma 2X protein expressionCell lymphoma 2Interleukin-10Peripheral bloodActive caspase-3Low-dose gamma irradiationCytokine secretionTregsLuminex assaysBlood samplesInduction of apoptosisCharacterization of Anti-HCV Antibodies in IL-10-Treated Patients
Eksioglu E, Bess J, Jones G, Dettloff J, Dangmeon P, Dong H, Zhu H, Firpi R, Xu Y, Nelson D, Liu C. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunology 2010, 23: 359-368. PMID: 20712480, PMCID: PMC2978060, DOI: 10.1089/vim.2009.0095.Peer-Reviewed Original ResearchConceptsAnti-HCV antibodiesAnti-HCV antibody titersIL-10Antibody titersTotal anti-HCV antibodyHepatitis C virus infectionC virus infectionChronic hepatitis patientsIL-10 treatmentReal-time reverse transcriptase-polymerase chain reactionReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHuh-7.5 cellsHCV-negative seraAntibody neutralization activityDisease activityHCV antibodiesViral burdenHepatitis patientsViral loadInterleukin-10Antibody responseReplicon cellsPolymerase chain reactionNeutralization antibody
2009
Immunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10–dependent manner
Toubai T, Malter C, Tawara I, Liu C, Nieves E, Lowler K, Sun Y, Reddy P. Immunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10–dependent manner. Blood 2009, 115: 724-735. PMID: 19965670, PMCID: PMC2810989, DOI: 10.1182/blood-2009-06-229708.Peer-Reviewed Original ResearchConceptsT cell responsesDendritic cellsT cellsImmune responseUndesirable immune responsesIL-10Major histocompatibilityDonor T-cell responsesIL-10-dependent mannerExperimental acute GVHDImmunization of donorsDonor T cellsAntigen-specific mannerB6 modelBALB/c T cellsCertain immune responsesBALB/cAcute GVHDHost diseaseInterleukin-10Active immunizationInflammatory cytokinesVaccination strategiesAntigen specificityGVHD
2005
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Zhu H, Butera M, Nelson D, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virology Journal 2005, 2: 80. PMID: 16146571, PMCID: PMC1232870, DOI: 10.1186/1743-422x-2-80.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsBase SequenceCell LineGenes, MHC Class IHepacivirusHepatitis CHumansInterferon Regulatory Factor-1Interferon Type IInterferon-alphaInterferon-Stimulated Gene Factor 3Interleukin-10InterleukinsJanus KinasesMolecular Sequence DataRNA, ViralSignal TransductionSTAT Transcription FactorsVirus ReplicationConceptsInterferon-stimulated genesIL-28AAntiviral activityAntiviral efficacyHuman hepatoma cellsSide effectsChronic hepatitis C viral infectionHepatitis C viral infectionViral RNA replicationAntiviral response ratesHCV subgenomic RNA replicationIFNα-based therapyGenotype 1 infectionHCV chronic infectionC viral infectionIL-10 receptorIL-10 treatmentHLA class IType I IFNJAK-STATRNA replicationDose-dependent mannerHepatoma cellsExpression of ISGsUndesirable side effects
2004
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera R, Tu Z, Xu Y, Firpi R, Rosen H, Liu C, Nelson D. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40: 1062-1071. PMID: 15486925, DOI: 10.1002/hep.20454.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesAntibody FormationAntigens, CDCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell CommunicationEpitopesHepatitis CHepatitis C AntigensHumansImmune SystemInterleukin-10PhenotypeReceptors, Interleukin-2Transforming Growth Factor betaTransforming Growth Factor beta1ConceptsHepatitis C virus infectionPeripheral blood mononuclear cellsC virus infectionRegulatory T lymphocytesBlood mononuclear cellsT lymphocytesMononuclear cellsVirus infectionHCV-specific T-cell responsesCell-cell contact mannerT cell immune responsesHCV RNA titersT cell frequenciesIL-10 productionT cell responsesCell immune responsesInterferon-gamma productionLiver inflammatory activityNormal control subjectsT cell proliferationInterferon gamma activityGrowth factor betaIL-10Intracellular cytokinesInflammatory activity
2003
Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect
Nelson D, Tu Z, Soldevila‐Pico C, Abdelmalek M, Zhu H, Xu Y, Cabrera R, Liu C, Davis G. Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect. Hepatology 2003, 38: 859-868. PMID: 14512873, DOI: 10.1002/hep.1840380412.Peer-Reviewed Original ResearchConceptsIL-10HCV RNASerum ALTCytokine productionChronic hepatitis C patientsFunctional T cell analysesSerum HCV RNA levelsHCV-specific CD4Hepatic inflammation scoresIL-10 administrationInterleukin-10 therapyPBMC cytokine productionTh2 dominant profileHCV RNA levelsHepatitis C patientsT cell analysisTh2 cytokine productionAnti-inflammatory effectsAcute flaresC patientsDisease activityMeq/mLViral burdenAdvanced fibrosisLiver biopsy